Inhibikase Therapeutics (IKT) Competitors $1.71 0.00 (0.00%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.72 +0.01 (+0.58%) As of 08/14/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT vs. ITOS, SNDL, CGEM, CMPS, KOD, TECX, PRTC, CAPR, PRTA, and REPLShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include iTeos Therapeutics (ITOS), SNDL (SNDL), Cullinan Therapeutics (CGEM), COMPASS Pathways (CMPS), Kodiak Sciences (KOD), Tectonic Therapeutic (TECX), PureTech Health (PRTC), Capricor Therapeutics (CAPR), Prothena (PRTA), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors iTeos Therapeutics SNDL Cullinan Therapeutics COMPASS Pathways Kodiak Sciences Tectonic Therapeutic PureTech Health Capricor Therapeutics Prothena Replimune Group iTeos Therapeutics (NASDAQ:ITOS) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Do insiders & institutionals have more ownership in ITOS or IKT? 97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 14.2% of iTeos Therapeutics shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, ITOS or IKT? Inhibikase Therapeutics has lower revenue, but higher earnings than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M12.77-$134.41M-$4.67-2.16Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.64 Which has more volatility & risk, ITOS or IKT? iTeos Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Do analysts prefer ITOS or IKT? iTeos Therapeutics presently has a consensus price target of $15.50, indicating a potential upside of 53.31%. Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 280.12%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ITOS or IKT more profitable? iTeos Therapeutics' return on equity of -33.26% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -33.26% -28.16% Inhibikase Therapeutics N/A -350.63%-201.82% Does the media prefer ITOS or IKT? In the previous week, iTeos Therapeutics had 7 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 8 mentions for iTeos Therapeutics and 1 mentions for Inhibikase Therapeutics. iTeos Therapeutics' average media sentiment score of 0.59 beat Inhibikase Therapeutics' score of 0.00 indicating that iTeos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iTeos Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryiTeos Therapeutics beats Inhibikase Therapeutics on 8 of the 13 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$127.13M$282.85M$5.61B$21.04BDividend YieldN/AN/A4.61%3.57%P/E Ratio-0.64N/A30.2728.08Price / SalesN/A570.35469.9557.05Price / CashN/A22.4438.2123.95Price / Book0.969.418.845.26Net Income-$19.03M-$115.81M$3.25B$994.11M7 Day Performance19.58%2.63%3.71%2.09%1 Month Performance-5.00%-0.34%5.85%2.35%1 Year Performance33.59%-2.92%30.25%13.36% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.7617 of 5 stars$1.71flat$6.50+280.1%+31.5%$127.13MN/A-0.646News CoverageITOSiTeos Therapeutics2.7362 of 5 stars$10.11flat$15.50+53.3%-33.0%$446.92M$35M-2.1690SNDLSNDL2.2368 of 5 stars$2.01+19.3%$4.00+99.5%-2.3%$441.46M$671.81M-7.432,516Options VolumeGap DownHigh Trading VolumeCGEMCullinan Therapeutics1.6498 of 5 stars$7.09-2.9%$30.00+323.1%-53.3%$430.95MN/A-2.2030CMPSCOMPASS Pathways2.6175 of 5 stars$4.34-1.1%$16.29+275.2%-38.3%$421.18MN/A-2.36120KODKodiak Sciences3.323 of 5 stars$8.03+1.6%$9.00+12.1%+293.7%$416.83MN/A-2.2190News CoverageEarnings ReportAnalyst UpgradeGap UpTECXTectonic Therapeutic2.4454 of 5 stars$22.11-0.9%$80.33+263.3%+52.4%$416.58MN/A-5.47120PRTCPureTech Health2.8012 of 5 stars$17.15-0.6%$45.00+162.4%-24.7%$416.27M$4.83M0.00100News CoverageShort Interest ↓Gap UpHigh Trading VolumeCAPRCapricor Therapeutics3.2146 of 5 stars$7.82-13.8%$22.56+188.4%+103.7%$414.29M$22.27M-5.51101Trending NewsEarnings ReportAnalyst RevisionPRTAProthena3.5405 of 5 stars$7.67-0.3%$30.25+294.4%-59.2%$413.95M$135.16M-1.36130REPLReplimune Group4.4862 of 5 stars$4.99-5.7%$7.67+53.6%-45.7%$412.92MN/A-1.54210Trending NewsShort Interest ↑ Related Companies and Tools Related Companies ITOS Alternatives SNDL Alternatives CGEM Alternatives CMPS Alternatives KOD Alternatives TECX Alternatives PRTC Alternatives CAPR Alternatives PRTA Alternatives REPL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access